Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 12, 2017, Pages 2837-2848

  Suschak, John J ^a   Williams, James A ^b   Schmaljohn, Connie S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATURE TECHNOLOGY CORPORATION   (United States)

Author keywords

DNA vaccine; Immunogenicity; Molecular adjuvant; Plasmid; Vaccine delivery

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; COLONY STIMULATING FACTOR 1; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; DRUG CARRIER;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; BACTERIUM CULTURE; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GENE SEQUENCE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MOLECULAR BIOLOGY; NATURAL KILLER T CELL; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PINOCYTOSIS; PLASMID; PROTEIN EXPRESSION; REVIEW; RNA PROCESSING; SIGNAL TRANSDUCTION; TECHNOLOGY; VACCINATION; VETERINARY MEDICINE; ANIMAL; DRUG DEVELOPMENT; GENE VECTOR; GENETICS; IMMUNOLOGY; TRENDS;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENETIC VECTORS; HUMANS; VACCINES, DNA;

EID: 85038845677     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1330236     Document Type: Review

References (173)

1. Galvin TA, Muller J, Khan AS. Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina. Vaccine 2000; 18:2566-83; https://doi.org/10.1016/S0264-410X (99)00569-1
2. Huang MT, Gorman CM. Intervening sequences increase efficiency of RNA 30 processing and accumulation of cytoplasmic RNA. Nucleic Acids Res 1990; 18:937-47; https://doi.org/10.1093/nar/18.4.937
3. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15:313-29.
4. Goulder PJ, Rowland-Jones SL, McMichael AJ, Walker BD. Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 1999; 13 Suppl A:S121-36.
5. Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004; 17:370-89; https://doi.org/10.1128/CMR.17.2.370-389.2004
6. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, et al. Induction of CD4(C) T cell-dependent CD8(C) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A 2001; 98:10817-22; https://doi. org/10.1073/pnas.181123498
7. Hollister K, Chen Y, Wang S, Wu H, Mondal A, Clegg N, Lu S, Dent A. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum Vaccin Immunother 2014; 10:1985-92; https://doi.org/10.4161/hv.28659
8. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; https://doi.org/10.1126/science.1690918
9. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; https://doi.org/10.1126/science.8456302
10. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-57; https://doi.org/10.1016/j.vaccine.2007.12.060 10.1016/j.vaccine.2007.12.024
11. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996; 173:314-20; https://doi. org/10.1093/infdis/173.2.314
12. Fuller DH, Haynes JR. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994; 10:1433-41; https://doi.org/10.1089/aid.1994.10.1433
13. Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 2011; 18:707-16; https://doi.org/10.1128/CVI.00030-11
14. Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 2010; 28:7345-50; https://doi.org/10.1016/j.vaccine.2010.09.005
15. Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccines Immunotherapeutics 2015; 11:1991-2004; https://doi.org/10.1080/21645515.2015.1039757
16. Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother 2012; 8:1703-6; https://doi.org/10.4161/hv.21873
17. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra138; https://doi.org/10.1126/scitranslmed.3004414
18. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252; https://doi.org/10.1371/journal. pone.0019252
19. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20:1269-78; https://doi.org/10.1089/hum.2009.067
20. Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 2014; 5:5317; https://doi.org/10.1038/ncomms6317
21. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4; https://doi.org/10.1038/356152a0
22. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, et al. Induction of antigenspecific CD8C T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19:764-78; https://doi.org/10.1016/S0264-410X(00)00302-9
23. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 21:4604-8; https://doi.org/10.1016/S0264-410X (03)00447-X
24. Choi AH, Smiley K, Basu M, McNeal MM, Shao M, Bean JA, Clements JD, Stout RR, Ward RL. Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. Vaccine 2007; 25:3215-8; https://doi.org/10.1016/j.vaccine.2007.01.035
25. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-7; https://doi.org/10.1128/CVI.05663-11
26. Aguiar JC, Hedstrom RC, Rogers WO, Charoenvit Y, Sacci JB, Jr, Lanar DE, Majam VF, Stout RR, Hoffman SL. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001; 20:275-80; https://doi.org/10.1016/S0264-410X(01)00273-0
27. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC. Comparison of the CD8C T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21:4036-42; https://doi.org/10.1016/S0264-410X(03)00275-5
28. Karkada M, Weir GM, Quinton T, Fuentes-Ortega A, Mansour M. A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine 2010; 28:6176-82; https://doi.org/10.1016/j.vaccine.2010.07.025
29. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, Silverman C, Alving CR. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 1992; 89:358-62; https://doi.org/10.1073/ pnas.89.1.358
30. Zollinger WD, Babcock JG, Moran EE, Brandt BL, Matyas GR, Wassef NM, Alving CR. Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. Vaccine 2012; 30:712-21; https://doi.org/10.1016/j.vaccine.2011.11.084
31. Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, Wloch MK, Tonsky K, Norman J, Manthorpe M, et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001; 19:1911-23; https://doi. org/10.1016/S0264-410X(00)00445-X
32. Reyes L, Hartikka J, Bozoukova V, Sukhu L, Nishioka W, Singh G, Ferrari M, Enas J, Wheeler CJ, Manthorpe M, et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 2001; 19:3778-86; https://doi.org/10.1016/S0264-410X (01)00090-1
33. Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24:1921-7
34. Sedegah M, Rogers WO, Belmonte M, Belmonte A, Banania G, Patterson NB, Rusalov D, Ferrari M, Richie TL, Doolan DL. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5 gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine 2010; 28:3055-65; https://doi.org/10.1016/j.vaccine.2009.10.044
35. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565-72; https://doi.org/10.1016/j.vaccine.2010.01.029
36. Liu J, Wu J, Wang B, Zeng S, Qi F, Lu C, Kimura Y, Liu B. Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection. J Med Virol 2014; 86:886-94; https://doi.org/10.1002/jmv.23768
37. Ma J, Wang H, Zheng X, Xue X, Wang B, Wu H, Zhang K, Fan S, Wang T, Li N, et al. CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice. Int Immunopharmacol 2014; 19:74-80; https://doi.org/10.1016/j.intimp.2014.01.002
38. Chen L, Zhu J, Li Y, Lu J, Gao L, Xu H, Fan M, Yang X. Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/ DNA complexes. PLoS One 2013; 8:e71953; https://doi.org/10.1371/journal.pone.0071953
39. Basarkar A, Devineni D, Palaniappan R, Singh J. Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide- co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm 2007; 343:247-54; https://doi.org/10.1016/j.ijpharm.2007.05.023
40. Mok H, Park TG. Direct plasmid DNA encapsulation within PLGA nanospheres by single oil-in-water emulsion method. Eur J Pharm Biopharm 2008; 68:105-11; https://doi.org/10.1016/j.ejpb.2007.04.022
41. Hao T, McKeever U, Hedley ML. Biological potency of microsphere encapsulated plasmid DNA. J Control Release 2000; 69:249-59; https://doi.org/10.1016/S0168-3659(00)00304-7
42. Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles:A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97:811-6; https://doi. org/10.1073/pnas.97.2.811
43. Aral C, Akbuga J. Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA:poly(L-lysine) complexes. J Pharm Pharm Sci 2003; 6:321-6.
44. Alexakis T, Boadi DK, Quong D, Groboillot A, O’Neill I, Poncelet D, Neufeld RJ. Microencapsulation of DNA within alginate microspheres and crosslinked chitosan membranes for in vivo application. Appl Biochem Biotechnol 1995; 50:93-106; https://doi.org/10.1007/BF02788043
45. Herrmann JE, Chen SC, Jones DH, Tinsley-Bown A, Fynan EF, Greenberg HB, Farrar GH. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 1999; 259:148-53; https://doi.org/10.1006/viro.1999.9751
46. Kaur R, Rauthan M, Vrati S. Immunogenicity in mice of a cationic microparticle-adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein. Vaccine 2004; 22:2776-82; https://doi.org/10.1016/j.vaccine.2004.01.040
47. Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005; 79:8189-200; https://doi.org/10.1128/JVI.79.13.8189-8200.2005
48. Wang F, He XW, Jiang L, Ren D, He Y, Li DA, Sun SH. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 2006; 24:2017-26; https://doi.org/10.1016/j.vaccine.2005.11.042
49. Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pietersz GA, Apostolopoulos V, Plebanski M. Poly-L-lysine-coated nanoparticles:a potent delivery system to enhance DNA vaccine efficacy. Vaccine 2007; 25:1316-27; https://doi.org/10.1016/j.vaccine.2006.09.086
50. He X, Jiang L, Wang F, Xiao Z, Li J, Liu LS, Li D, Ren D, Jin X, Li K, et al. Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. J Control Release 2005; 107:357-72; https://doi.org/10.1016/j.jconrel.2005.06.020
51. Mollenkopf HJ, Dietrich G, Fensterle J, Grode L, Diehl KD, Knapp B, Singh M, O’Hagan DT, Ulmer JB, Kaufmann SH. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 2004; 22:2690-5; https://doi.org/10.1016/j.vaccine.2004.05.005
52. Luo Y, O’Hagan D, Zhou H, Singh M, Ulmer J, Reisfeld RA, James Primus F, Xiang R. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003; 21:1938-47; https://doi.org/10.1016/S0264-410X(02)00821-6
53. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008; 451:725-9; https:// doi.org/10.1038/nature06537
54. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 2005; 202:1333-9; https://doi.org/10.1084/jem.20051654
55. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006; 24:93-103; https://doi.org/10.1016/j. immuni.2005.12.003
56. Spies B, Hochrein H, Vabulas M, Huster K, Busch DH, Schmitz F, Heit A, Wagner H. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9- deficient mice. J Immunol 2003; 171:5908-12; https://doi.org/10.4049/jimmunol.171.11.5908
57. Babiuk S, Mookherjee N, Pontarollo R, Griebel P, van Drunen Littel-van den Hurk S, Hecker R, Babiuk L. TLR9¡/¡ and TLR9C/ C mice display similar immune responses to a DNA vaccine. Immunology 2004; 113:114-20; https://doi.org/10.1111/j.1365-2567.2004.01938.x
58. Kojima Y, Xin KQ, Ooki T, Hamajima K, Oikawa T, Shinoda K, Ozaki T, Hoshino Y, Jounai N, Nakazawa M, Klinman D, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002; 20:2857-65; https://doi.org/10.1016/S0264-410X(02)00238-4
59. Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 2005; 78:647-55; https://doi.org/10.1189/jlb.1104627
60. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32; https://doi.org/10.1007/s12026-008-8076-3
61. Laddy DJ, Weiner DB. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25:99-123; https://doi.org/10.1080/08830180600785827
62. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013; 4:354; https://doi.org/10.3389/ fimmu.2013.00354
63. Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrison LD, Javadian A, Chalian AA, Agadjanyan MG, Weiner DB. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 1998; 16:1828-35; https:// doi.org/10.1016/S0264-410X(98)00177-7
64. Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999; 19:77-84; https://doi.org/10.1089/107999099314441
65. Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine 2004; 22:3092-7; https://doi.org/10.1016/ j.vaccine.2004.01.065
66. Henke A, Rohland N, Zell R, Wutzler P. Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Intervirology 2006; 49:249-52; https://doi.org/10.1159/000092487
67. Hu H, Tao L, Wang Y, Chen L, Yang J, Wang H. Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice. Biotechnol Lett 2009; 31:1685-93; https://doi.org/10.1007/s10529-009-0061-y
68. Qin Y, Tian H, Wang G, Lin C, Li Y. A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice. Biomed Res Int 2013; 2013:136492; https://doi.org/10.1155/2013/136492
69. McGill J, Van Rooijen N, Legge KL. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J Exp Med 2010; 207:521-34; https://doi.org/10.1084/jem.20091711
70. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168:4827-31; https://doi.org/10.4049/jimmunol.168.10.4827
71. Yajima T, Yoshihara K, Nakazato K, Kumabe S, Koyasu S, Sad S, Shen H, Kuwano H, Yoshikai Y. IL-15 regulates CD8C T cell contraction during primary infection. J Immunol 2006; 176:507-15; https://doi.org/10.4049/jimmunol.176.1.507
72. Combe CL, Moretto MM, Schwartzman JD, Gigley JP, Bzik DJ, Khan IA. Lack of IL-15 results in the suboptimal priming of CD4C T cell response against an intracellular parasite. Proc Natl Acad Sci U S A 2006; 103:6635-40; https://doi.org/10.1073/ pnas.0506180103
73. Ruckert R, Brandt K, Bulanova E, Mirghomizadeh F, Paus R, Bulfone-Paus S. Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur J Immunol 2003; 33:3493-503; https://doi.org/10.1002/eji.200324545
74. Chen J, Li ZY, Huang SY, Petersen E, Song HQ, Zhou DH, Zhu XQ. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice. BMC Infect Dis 2014; 14:487; https://doi.org/10.1186/1471-2334-14-487
75. Li ZY, Chen J, Petersen E, Zhou DH, Huang SY, Song HQ, Zhu XQ. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine 2014; 32:3058-65; https://doi.org/10.1016/j.vaccine.2014.03.042
76. Su B, Wang J, Zhao G, Wang X, Li J, Wang B. Sequential administration of cytokine genes to enhance cellular immune responses and CD4 (C) T memory cells during DNA vaccination. Hum Vaccin Immunother 2012; 8:1659-67; https://doi.org/10.4161/hv.22105
77. Bergamaschi C, Kulkarni V, Rosati M, Alicea C, Jalah R, Chen S, Bear J, Sardesai NY, Valentin A, Felber BK, et al. Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther 2015; 22:76-86; https://doi.org/10.1038/gt.2014.84
78. Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, Parkinson R, Wu L, Sidhu MK, Pavlakis GN, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007; 104:18648-53; https://doi.org/10.1073/pnas.0709198104
79. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of TH1 CD4C T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9; https://doi.org/10.1126/science.8097338
80. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG. Resolution of cutaneous leishmaniasis:interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177:1797-802; https://doi.org/10.1084/jem.177.6.1797
81. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O’Garra A. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4C T cells. J Immunol 1995; 154:5071-9.
82. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170:827-45; https://doi.org/10.1084/ jem.170.3.827
83. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243.
84. Hunter CA, Chizzonite R, Remington JS. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 1995; 155:4347-54.
85. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148:92-8.
86. Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP, Sampognaro S, Maggi E, Romagnani S, Trinchieri G, et al. Interleukin 12 induces stable priming for interferon gamma (IFNgamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179:1273-83; https://doi. org/10.1084/jem.179.4.1273
87. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818-29; https://doi.org/10.1093/infdis/jit236
88. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B, Weiner DB. Development of a multicomponent candidate vaccine for HIV-1. Vaccine 1997; 15:879-83; https:// doi.org/10.1016/S0264-410X(96)00260-5
89. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112-20; https://doi.org/10.1016/j.vaccine.2008.02.036
90. Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Sidhu MK, Muthumani K, Lewis M, Pavlakis G, Felber B, et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005; 34:262-70; https:// doi.org/10.1111/j.1600-0684.2005.00124.x
91. Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007; 25:4967-82; https://doi.org/10.1016/j.vaccine.2006.11.070
92. Robinson TM, Sidhu MK, Pavlakis GN, Felber BK, Silvera P, Lewis MG, Eldridge J, Weiner DB, Boyer JD. Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses. J Med Primatol 2007; 36:276-84; https://doi.org/10.1111/j.1600-0684.2007.00245.x
93. Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Setlik A, Geltz JJ, Halford WP, Fouts TR. An interleukin 12 adjuvanted herpes simplex virus 2 DNA vaccine is more protective than a glycoprotein D subunit vaccine in a high-dose murine challenge model. Viral Immunol. 2017; 30:178-95; https:// doi.org/10.1089/vim.2016.0136
94. Morrow MP, Yan J, Pankhong P, Ferraro B, Lewis MG, Khan AS, Sardesai NY, Weiner DB. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12(IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010; 17:1493-9; https://doi.org/10.1128/CVI.00181-10
95. Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 2009; 27:1306-16; https://doi.org/10.1016/ j.vaccine.2008.12.053
96. Yamanaka H, Hoyt T, Yang X, Golden S, Bosio CM, Crist K, Becker T, Maddaloni M, Pascual DW. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun 2008; 76:4564-73; https://doi.org/10.1128/IAI.00581-08
97. Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, Garcia-Hand D, Cappello S, Roopchand V, Megati S, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006; 24:4677-87; https://doi.org/10.1016/j.vaccine.2005.10.035
98. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, Parkinson R, Wu L, Sidhu MK, Phillipson-Weiner R, et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA C IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008; 180:7969-79; https://doi.org/10.4049/ jimmunol.180.12.7969
99. Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, Alicea C, Hannaman D, Reed SG, Felber BK, Pavlakis GN. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013; 31:3747-55; https://doi.org/10.1016/j.vaccine.2013.04.037
100. Cha E, Daud A. Plasmid IL-12 electroporation in melanoma. Hum Vaccin Immunother 2012; 8:1734-8; https://doi. org/10.4161/hv.22573
101. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999; 73:6721-8.
102. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231; https://doi.org/10.1371/journal.pone.0029231
103. Yang SH, Lee CG, Park SH, Im SJ, Kim YM, Son JM, Wang JS, Yoon SK, Song MK, Ambrozaitis A, et al. Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006; 13:1110-7.
104. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000; 165:3772-81.
105. Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, Klinman DM, Hoffman SL. A plasmid encoding murine granulocyte- macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161:2325-32.
106. Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci U S A 2002; 99:13020-5.
107. Yoon HA, Aleyas AG, George JA, Park SO, Han YW, Lee JH, Cho JG, Eo SK. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol 2006; 50:83-92.
108. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid- encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2:129-35.
109. Santana VC, Almeida RR, Ribeiro SP, Ferreira LC, Kalil J, Rosa DS, Cunha-Neto E. Co-administration of plasmid-encoded granulocyte- macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4C T-cell responses. Mem Inst Oswaldo Cruz 2015; 110:1010-6.
110. Chen H, Gao N, Wu J, Zheng X, Li J, Fan D, An J. Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice. Immunol Lett 2014; 162:140-8.
111. Kumar S, Villinger F, Oakley M, Aguiar JC, Jones TR, Hedstrom RC, Gowda K, Chute J, Stowers A, Kaslow DC, et al. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunol Lett 2002; 81:13-24.
112. Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007; 13:540-9; https:// doi.org/10.1158/1078-0432.CCR-06-2039
113. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004; 202:266-74; https://doi.org/10.1111/j.0105-2896.2004.00200.x
114. Wan C, Yi L, Yang Z, Yang J, Shao H, Zhang C, Pan Z. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Vet Immunol Immunopathol 2010; 137:47-53; https://doi.org/10.1016/j.vetimm.2010.04.008
115. Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006; 80:6218-24; https://doi.org/10.1128/JVI.00121-06
116. Liniger M, Summerfield A, Ruggli N. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS One 2012; 7:e49952; https://doi.org/10.1371/ journal.pone.0049952
117. Luke JM, Simon GG, Soderholm J, Errett JS, August JT, Gale M, Jr., Hodgson CP, Williams JA. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011; 85:1370-83; https://doi.org/10.1128/ JVI.01250-10
118. Yang B, Yang A, Peng S, Pang X, Roden RB, Wu TC, Hung CF. Coadministration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci 2015; 5:35; https://doi. org/10.1186/s13578-015-0025-y
119. Massa S, Paolini F, Spano L, Franconi R, Venuti A. Mutants of plant genes for developing cancer vaccines. Hum Vaccin 2011; 7 Suppl:147-55; https://doi.org/10.4161/hv.7.0.14577
120. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004; 11:1011-8; https://doi.org/10.1038/sj.gt.3302252
121. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG, 2nd, Niu Z, Denisova L, Follmer TT, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000; 43:273-81; https://doi.org/10.1159/000053994
122. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 1995; 772:30-9; https://doi.org/10.1111/j.1749-6632.1995. tb44729.x
123. Sorensen SJ, Bailey M, Hansen LH, Kroer N, Wuertz S. Studying plasmid horizontal transfer in situ: a critical review. Nat Rev Microbiol 2005; 3:700-10; https://doi.org/10.1038/ nrmicro1232
124. Oliveira PH, Mairhofer J. Marker-free plasmids for biotechnological applications - implications and perspectives. Trends Biotechnol 2013; 31:539-47; https://doi.org/10.1016/j. tibtech.2013.06.001
125. Williams JA. Improving DNA vaccine performance through vector design. Curr Gene Ther 2014; 14:170-89; https:// doi.org/10.2174/156652321403140819122538
126. Kreiss P, Cameron B, Rangara R, Mailhe P, Aguerre-Charriol O, Airiau M, Scherman D, Crouzet J, Pitard B. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 1999; 27:3792-8; https://doi.org/10.1093/nar/27.19.3792
127. Yin W, Xiang P, Li Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal Biochem 2005; 346:289-94; https://doi.org/10.1016/j. ab.2005.08.029
128. Hornstein BD, Roman D, Arevalo-Soliz LM, Engevik MA, Zechiedrich L. Effects of circular DNA length on transfection efficiency by electroporation into HeLa Cells. PLoS One 2016; 11:e0167537; https://doi.org/10.1371/journal. pone.0167537
129. Stenler S, Wiklander OP, Badal-Tejedor M, Turunen J, Nordin JZ, Hallengard D, Wahren B, Andaloussi SE, Rutland MW, Smith CE, et al. Micro-minicircle Gene therapy: Implications of size on fermentation, complexation, shearing resistance, and expression. Mol Ther Nucleic Acids 2014; 2:e140; https://doi.org/10.1038/mtna.2013.67
130. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem 2000; 275:1625-9; https:// doi.org/10.1074/jbc.275.3.1625
131. Marie C, Vandermeulen G, Quiviger M, Richard M, Preat V, Scherman D. pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J Gene Med 2010; 12:323-32; https://doi.org/10.1002/jgm.1441
132. Carnes AE, Luke JM, Vincent JM, Anderson S, Schukar A, Hodgson CP, Williams JA. Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields. J Gene Med 2010; 12:818-31; https://doi. org/10.1002/jgm.1499
133. Ribeiro S, Mairhofer J, Madeira C, Diogo MM, Lobato da Silva C, Monteiro G, Grabherr R, Cabral JM. Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cell Reprogram 2012; 14:130-7.
134. Wang Q, Jiang W, Chen Y, Liu P, Sheng C, Chen S, Zhang H, Pan C, Gao S, Huang W. In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses. J Virol 2013; 88:1924-34; https://doi.org/10.1128/JVI.02757-13
135. Lu J, Zhang F, Xu S, Fire AZ, Kay MA. The extragenic spacer length between the 50 and 30 ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors. Mol Ther 2012; 20:2111-9; https://doi.org/10.1038/ mt.2012.65
136. Gracey Maniar LE, Maniar JM, Chen ZY, Lu J, Fire AZ, Kay MA. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther 2013; 21:131-8; https://doi.org/10.1038/ mt.2012.244
137. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8:495-500; https://doi.org/10.1016/S1525-0016(03)00168-0
138. Simcikova M, Prather KL, Prazeres DM, Monteiro GA. Towards effective non-viral gene delivery vector. Biotechnol Genet Eng Rev 2015; 31:82-107; https://doi.org/10.1080/02648725.2016.1178011
139. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16:126-31; https://doi.org/10.1089/ hum.2005.16.126
140. Nelson J, Rodriguez S, Finlayson N, Williams J, Carnes A. Antibiotic- free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process. Hum Vaccin Immunother 2013; 9:2211-5; https://doi.org/10.4161/hv.25048
141. Lu J, Zhang F, Kay MA. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol Ther 2013; 21:954-63; https://doi.org/10.1038/mt.2013.33
142. Williams JA. Replicative minicircle vectors with improved expression. Nature Technology Corporation, US 2014; PCT/US2013/000259, WO2014/077,866, US 2015/0275221.
143. Pandey S, Kawai T, Akira S. Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb Perspect Biol 2014; 7:a016246; https://doi.org/10.1101/ cshperspect.a016246
144. Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P. Priming of CD8C T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine 2007; 25:6341-7; https://doi.org/10.1016/j.vaccine.2007.06.016
145. Rottembourg D, Filippi CM, Bresson D, Ehrhardt K, Estes EA, Oldham JE, von Herrath MG. Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. J Immunol 2010; 184:7100-7; https://doi.org/10.4049/ jimmunol.0803935
146. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 2011; 128:473-81; https://doi.org/10.1002/ijc.25344
147. Yu YZ, Li N, Ma Y, Wang S, Yu WY, Sun ZW. Three types of human CpG motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built-in adjuvants. Eur J Immunol 2013; 43:228-39; https://doi.org/10.1002/eji.201242690
148. Arsenault RJ, Kogut MH, He H. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands. Cell Signal 2013; 25:2246-54; https://doi.org/10.1016/j.cellsig.2013.07.014
149. Gutjahr A, Tiraby G, Perouzel E, Verrier B, Paul S. Triggering intracellular receptors for vaccine adjuvantation. Trends Immunol 2016; 37:573-87; https://doi.org/10.1016/j.it.2016.07.00110.1016/j.it.2016.08.005
150. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 2014; 32:461-88; https://doi.org/10.1146/annurev-immunol-032713-120156
151. Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, Akira S, Klinman DM, Ishii KJ. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14CCD11cC monocytes. J Immunol 2005; 174:2273-9; https:// doi.org/10.4049/jimmunol.174.4.2273
152. Wu J, Ma H, Qu Q, Zhou WJ, Luo YP, Thangaraj H, Lowrie DB, Fan XY. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice. Vaccine 2011; 29:7624-30; https://doi. org/10.1016/j.vaccine.2011.08.020
153. Hochheiser K, Klein M, Gottschalk C, Hoss F, Scheu S, Coch C, Hartmann G, Kurts C. Cutting edge: The RIG-I ligand 3pRNA potently improves CTL cross-priming and facilitates antiviral vaccination. J Immunol 2016; 196:2439-43; https://doi. org/10.4049/jimmunol.1501958
154. Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, Davis C, Marisetti K, Thomas S, Gangappa S, Sambhara S, et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol 2014; 88:13990-4001; https://doi.org/10.1128/JVI.02273-14
155. Beljanski V, Chiang C, Kirchenbaum GA, Olagnier D, Bloom CE, Wong T, Haddad EK, Trautmann L, Ross TM, Hiscott J. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J Virol 2015; 89:10612-24; https://doi.org/10.1128/JVI.01526-15
156. Zevini A, Olagnier D, Hiscott J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 2017; 38:194-205; https://doi.org/10.1016/j.it.2016.12.004
157. Suschak JJ, Wang S, Fitzgerald KA, Lu S. Identification of aim2 as a sensor for DNA vaccines. J Immunol 2015; 194:630-6; https://doi.org/10.4049/jimmunol.1402530
158. Suschak JJ, Wang S, Fitzgerald KA, Lu S. A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol 2016; 196:310-6; https://doi.org/10.4049/jimmunol.1501836
159. Borggren M, Nielsen J, Bragstad K, Karlsson I, Krog JS, Williams JA, Fomsgaard A. Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans. Hum Vaccin Immunother 2015; 11:1983-90; https://doi.org/10.1080/21645515.2015.1011987
160. Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines 2013; 1:225-249; https://doi.org/10.3390/vaccines1030225
161. Sin JI, Kim JJ, Zhang D, Weiner DB. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen- specific helper T cell type 1 CD4C T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum Gene Ther 2001; 12:1091-102; https://doi.org/10.1089/104303401750214302
162. Agadjanyan MG, Chattergoon MA, Holterman MJ, Monzavi-Karbassi B, Kim JJ, Dentchev T, Wilson D, Ayyavoo V, Montaner LJ, Kieber-Emmons T, et al. Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86. J Immunol 2003; 171:4311-9; https://doi.org/10.4049/jimmunol.171.8.4311
163. Kim JJ, Yang JS, Lee DJ, Wilson DM, Nottingham LK, Morrison L, Tsai A, Oh J, Dang K, Dentchev T, et al. Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. Hum Gene Ther 2000; 11:305-21; https://doi.org/10.1089/10430340050016049
164. Kim JJ, Tsai A, Nottingham LK, Morrison L, Cunning DM, Oh J, Lee DJ, Dang K, Dentchev T, Chalian AA, et al. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. J Clin Invest 1999; 103:869-77; https://doi.org/10.1172/JCI6024
165. Kim JJ, Yang JS, Montaner L, Lee DJ, Chalian AA, Weiner DB. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J Interferon Cytokine Res 2000; 20:311-9; https://doi.org/10.1089/107999000312450
166. Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28:1089-103; https://doi.org/10.1002/(SICI)1521-4141(199803)28:03%3c1089::AID-IMMU1089%3e3.0.CO;2-L
167. Boyer JD, Nath B, Schumann K, Curley E, Manson K, Kim J, Weiner DB. IL-4 increases Simian immunodeficiency virus replication despite enhanced SIV immune responses in infected rhesus macaques. Int J Parasitol 2002; 32:543-50; https://doi. org/10.1016/S0020-7519(01)00355-1
168. Sin JI, Kim J, Pachuk C, Weiner DB. Interleukin 7 can enhance antigen- specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. Clin Diagn Lab Immunol 2000; 7:751-8.
169. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, Dang K, Hu Y, Kazahaya K, Bennett M, et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998; 102:1112-24; https:// doi.org/10.1172/JCI3986
170. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen- specific Th1-type CD4(C) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 2000; 74:11173-80; https://doi.org/10.1128/ JVI.74.23.11173-11180.2000
171. Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 2004; 22:1744-50; https://doi.org/10.1016/j. vaccine.2004.01.036
172. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175:112-23; https://doi.org/10.4049/ jimmunol.175.1.112
173. Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, Dentchev T, Manson KH, Wyand MS, Agadjanyan MG, et al. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol 1999; 28:214-23; https://doi. org/10.1111/j.1600-0684.1999.tb00272.x